Initial $35 Million to Produce 100,000 Ebola Sudan Vaccines

EverGlade Consulting today announced that Sabin Vaccine Institute successfully secured up to $214 million in funding from the U.S. government to advance the development and production of single-dose vaccine candidates for Ebola Sudan and Marburg virus diseases.

Currently, no licensed vaccines against either virus cause hemorrhagic fever and kill approximately half the people infected.

There are U.S. Food and Drug Administration-approved vaccines for a different ebolavirus known as Zaire.

BARDA, part of the U.S. Department of Health and Human Services' Administration for Strategic Preparedness and Response, will initially invest $35 million to produce up to 100,000 doses of the ChAd3-SUDV Ebola Sudan virus vaccine candidate.

These vaccines may be part of ongoing U.S. preparedness efforts and response to future global outbreaks.

The contract also includes funding to manufacture Sabin's Marburg virus vaccine, ChAd3-MARV, which will generate doses that could be used in trials and response to a future Marburg virus outbreak.

Andrew Stiles, Principal at EverGlade, said in a press release on January 25, 2023, "The recent Ebola Sudan outbreak in Uganda emphasized the critical need for better preparedness."

The initial Ebola virus disease (EVD) case first appeared in 1976.

The recent Sudan Ebolavirus outbreak in the Republic of Uganda was declared on September 20, 2022, and was declared ended in early 2023.

Detailed ebola vaccine information is posted at PrecisionVaccinations.com/Ebola.